By Rob Curran
BioNTech, the German biotech that rose to fame when it partnered with Pfizer on a Covid 19 vaccine, named Novartis executive Ramón Zapata-Gomez as chief financial officer, succeeding Jens Holstein upon the latter's retirement in June.
The company had previously disclosed Holstein's plans to retire on June 30, at which time Zapata-Gomez, who has served as the chief financial officer of Swiss drug maker's Novartis's biomedical research unit since 2022.
Zapata-Gomez's experience will help BioNTech reinvent itself as a multi-product company with an emphasis on oncology, the company said. In addition to his work at Novartis, Zapata-Gomez has held financial positions at generic-drug maker Sandoz AG, and consumer-products giant Mondelēz International.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 05, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.